Abiraterone-induced rhabdomyolysis: A case report. (March 2017)

• Record Type: Journal Article
• Authors: Moore, Donald C; Moore, Andrew
• Is Part Of: Journal of oncology pharmacy practice. Volume 23:Number 2(2017)
• Page Start: 148
• Page End: 151
• Publication Date: 2017-03
• Subjects: Abiraterone -- rhabdomyolysis -- toxicity; Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/1078155215620921
• Languages: English
• ISSNs: 1078-1552

Abstract

Abiraterone is an inhibitor of androgen biosynthesis indicated for the treatment of metastatic castration-resistant prostate cancer. Common side effects include diarrhea, edema, hypokalemia, hypertension, and liver function test abnormalities. We report a case of rhabdomyolysis developing in association with the use of abiraterone. Following discontinuation of abiraterone, creatine kinase concentrations decreased gradually throughout the duration of the hospitalization.